Teva Pharmaceutical Industries (BSP:T1EV34) Short Percentage of Float


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
11 GF Score
Price R$89.28
GF Value R$52.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BSP:T1EV34 vs ZTS, UTHR, VTRS: Short Percentage of Float Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Short Percentage of Float falls into.


BSP:T1EV34
11GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$89.28 is trading 70% above its estimated GF Value™ of R$52.51. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for BSP:T1EV34:

  • Short Percentage of Float:
  • GF Value™: R$52.51 vs. price of R$89.28 (70% above fair value)
  • GF Score™: 11/100 with 5 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
11GF Score

Get the complete analysis for BSP:T1EV34

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$89.28
Price
R$52.51
GF Value